- Home
- CNNE vs MNKD Comparison
CNNE vs MNKD Comparison
Compare CNNE & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNNE
- MNKD
- Stock Information
- Founded
- CNNE 2014
- MNKD 1991
- Country
- CNNE United States
- MNKD United States
- Employees
- CNNE N/A
- MNKD N/A
- Industry
- CNNE Restaurants
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- CNNE Consumer Discretionary
- MNKD Health Care
- Exchange
- CNNE Nasdaq
- MNKD Nasdaq
- Market Cap
- CNNE 1.1B
- MNKD 1.4B
- IPO Year
- CNNE N/A
- MNKD 2004
- Fundamental
- Price
- CNNE $18.77
- MNKD $4.27
- Analyst Decision
- CNNE Buy
- MNKD Strong Buy
- Analyst Count
- CNNE 2
- MNKD 5
- Target Price
- CNNE $22.00
- MNKD $9.40
- AVG Volume (30 Days)
- CNNE 647.9K
- MNKD 1.9M
- Earning Date
- CNNE 05-12-2025
- MNKD 05-08-2025
- Dividend Yield
- CNNE 2.57%
- MNKD N/A
- EPS Growth
- CNNE N/A
- MNKD 228.27
- EPS
- CNNE N/A
- MNKD 0.10
- Revenue
- CNNE $445,000,000.00
- MNKD $297,595,000.00
- Revenue This Year
- CNNE N/A
- MNKD $14.36
- Revenue Next Year
- CNNE $1.91
- MNKD $13.36
- P/E Ratio
- CNNE N/A
- MNKD $40.01
- Revenue Growth
- CNNE N/A
- MNKD 32.50
- 52 Week Low
- CNNE $15.92
- MNKD $4.05
- 52 Week High
- CNNE $22.36
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- CNNE 56.86
- MNKD 39.67
- Support Level
- CNNE $17.43
- MNKD $4.07
- Resistance Level
- CNNE $19.03
- MNKD $4.25
- Average True Range (ATR)
- CNNE 0.52
- MNKD 0.15
- MACD
- CNNE 0.06
- MNKD -0.02
- Stochastic Oscillator
- CNNE 73.44
- MNKD 20.39
About CNNE Cannae Holdings Inc.
Cannae Holdings Inc is a holding company that manages and operates a group of companies and investments. The company's reportable segments are Restaurant Group, Dun & Bradstreet, Alight, BKFC, Corporate and Other. Majority of the company's revenue is generated from its Restaurant Group segment which represents the operations of O'Charley's and Ninety Nine Restaurants.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.